ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

16 Tips from 16 Years Sick

Fibromyalgia Fare Fit for All Seasons

New Study Shows Artificial Sweeteners Lead to Diabetes

Essential Oils — An Effective and Healthy Option to Treat Headaches

Antioxidant treatment could halt neurodegeneration in early Parkinson's

Higher vitamin D levels associated with less severe disease in NAFLD patients

Krill Oil: Make This Omega-3 Supplement Part of Your Health Regimen

How zinc helps fight esophageal cancer

Everything You Need to Know About Black Cohosh

Low vitamin D levels predict ED in diabetics

 
Print Page
Email Article

Recruitment Has Begun for the Osteoarthritis Initiative (March 2004)

  [ 88 votes ]   [ Discuss This Article ]
www.ProHealth.com • March 17, 2004


NIH News National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) http://www.niams.nih.gov/ FOR IMMEDIATE RELEASE Wednesday, March 17, 2004 CONTACT: Liz Freedman 301-496-8190 freedmae@mail.nih.gov

ENROLLMENT BEGINS FOR OSTEOARTHRITIS INITIATIVE

Recruitment has begun for the Osteoarthritis Initiative (OAI), a public-private partnership between the National Institutes of Health and industry that funds a multisite contract to create a resource to hasten discovery of biological markers for osteoarthritis (OA). Men and women age 45 and older at risk for developing OA and those with early disease are eligible to participate. After an initial screening, four centers around the United States plan to each enroll and follow 1,250 adults for five years (total enrollment of 5,000). Biological specimens (blood, urine, DNA), images (X-rays and magnetic resonance scans) and clinical data will be collected annually.

Biological markers -- physical signs or biological substances that indicate changes in bone or cartilage -- are critical in diagnosing and monitoring OA and developing new treatments. Ultimately, results from the OAI may enable doctors to use biological markers to help identify people at risk for OA and people with OA at risk for disease progression. The markers could also help doctors assess the effectiveness of treatments.

The four clinical centers, selected in the summer of 2002, include the University of Maryland School of Medicine/Johns Hopkins University, the Ohio State University Medical Center, the University of Pittsburgh and the Memorial Hospital of Rhode Island/Brown University. A data coordinating center at the University of California, San Francisco oversees the study conduct and will manage the resulting data. The Ohio State University and University of Pittsburgh centers enrolled their first participants the week of February 23, and centers in Maryland and Rhode Island will begin enrollment in late March and early April.
The clinical centers may be contacted at:
Ms. Raushanah Kareem University of Maryland 10 South Pine Street, Room 8-34, MSTF Baltimore, MD 21201 (410) 706-5791 or (866) 565-KNEE (toll free)
Osteoarthritis Initiative The Ohio State University 198 McCampbell Hall 1581 Dodd Drive Columbus, OH 43210 (614) 688-3563 or (800) 251-1175 (toll free)
Study Office/GSPH University of Pittsburgh 4200 Fifth Avenue Pittsburgh, PA 15213-9910 (800) 872-3653 (toll free)
Osteoarthritis Initiative Memorial Hospital of Rhode Island/Brown University ATTN: Doris Moore 111 Brewster Street, CPCP Building, 2nd Floor Pawtucket, RI 02860 (800) 877-3347 (toll free)

Osteoarthritis, a degenerative condition whose hallmarks are joint pain and limited movement resulting from progressive loss of cartilage, is the most common type of arthritis, especially among older people. It can occur in any joint, but most often affects the hands, knees, hips or spine. There are currently no treatments, other than surgical joint replacement, that significantly change the course of this joint disease, and clinical trials for new therapies are long, difficult and expensive.

The OAI is a federal contract funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institute on Aging (NIA), Office of Research on Women's Health, National Institute of Dental and Craniofacial Research, National Center on Minority Health and Health Disparities and National Center for Complementary and Alternative Medicine, all part of the Department of Health and Human Services' National Institutes of Health. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation; and Pfizer Inc.

Private sector funding for the OAI is being managed by the Foundation for the National Institutes of Health. For information on the OAI, visit "The OAI: A Knee Health Study" at http://www.oai.ucsf.edu/clinics.asp. For general questions, visit http://www.niams.nih.gov/ne/press/2001/07_17qa.htm. The NIAMS Office of Communications and Public Liaison (301-496- 8190) or the NIA Communications Office (301-496-1752) can also be contacted for information.

The mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the Department of Health and Human Services' National Institutes of Health, is to support research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases, the training of basic and clinical scientists to carry out this research, and the dissemination of information on research progress in these diseases. For more information about NIAMS, call the information clearinghouse at (301) 495-4484 or (877) 22- NIAMS (free call) or visit the NIAMS Web site at http://www.niams.nih.gov.



Post a Comment

Featured Products From the ProHealth Store
Ultra EPA  - Fish Oil Mitochondria Ignite™ with NT Factor® Ultra ATP+, Double Strength


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

Natural Support for Mood, Sleep and Mental Focus? L-theanine Natural Support for Mood, Sleep and Mental Focus? L-theanine
Live Without Anxiety or Stress Live Without Anxiety or Stress
Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery Energy Breakthrough - One Fibromyalgia Patient’s Fortuitous Discovery
Green Coffee Extract: Unique Obesity Intervention Green Coffee Extract: Unique Obesity Intervention
The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health The Revolutionary 'Good Fat' That Promotes Heart, Brain, Bone and Joint Health

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map